Publications by authors named "Philippe Costet"

Claim this Profile
F
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor.
Sharif I Soleman, Juan Maya, Paul Levesque, Atif Mohammad, Lisa Christopher, Philippe Costet

Clin Pharmacol Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is atrial fibrillation in HFpEF a distinct phenotype? Insights from multiparametric MRI and circulating biomarkers.
Abhishek Dattani, Emer M Brady, Prathap Kanagala, Svetlana Stoma, Kelly S Parke, Philippe Costet

BMC Cardiovasc Disord· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of diabetes on remodelling, microvascular function and exercise capacity in aortic stenosis.
Abhishek Dattani, Emer M Brady, Aseel Alfuhied, Gaurav S Gulsin, Christopher D Steadman, Philippe Costet

Open Heart· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis.
Ji Zhang, Eric S Muise, Seongah Han, Peter S Kutchukian, Philippe Costet

Cell Rep Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.
Cédric Le May, Jean Mathieu Berger, Anne Lespine, Bruno Pillot, Xavier Prieur, Philippe Costet

Arterioscler Thromb Vasc Biol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor.
Simon Ducheix, Alexandra Montagner, Arnaud Polizzi, Frédéric Lasserre, Alice Marmugi, Philippe Costet

J Hepatol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury.
Maëlle Le Bras, Antoine Roquilly, Valérie Deckert, Cédric Langhi, Fanny Feuillet, Philippe Costet

J Clin Endocrinol Metab· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European lipoprotein club: report of the 35th ELC annual conference (Tutzing, 10th-13th September 2012).
Philippe Costet, Ewa Ehrenborg, Rachel Fisher, Barbara Fielding, Albert Groen

Atherosclerosis· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets.
Bertrand Cariou, Cédric Langhi, Maëlle Le Bras, Murielle Bortolotti, Kim-Anne Lê, Philippe Costet

Nutr Metab (Lond)· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European Lipoprotein Club: Report of the 34th ELC annual conference, Tutzing, 5-8 September 2011.
Franco Bernini, Philippe Costet, Ewa Ehrenborg, Rachel Fisher, Barbara Fielding

Atherosclerosis· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
Bruno Vergès, Laurence Duvillard, Marie Claude Brindisi, Emmanuel Gautier, Michel Krempf, Philippe Costet

Atherosclerosis· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical aspects of PCSK9.
Bertrand Cariou, Cédric Le May, Philippe Costet

Atherosclerosis· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients.
Bertrand Cariou, Maëlle Le Bras, Cédric Langhi, Cédric Le May, Béatrice Guyomarc'h-Delasalle, Philippe Costet

Atherosclerosis· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular pathways and agents for lowering LDL-cholesterol in addition to statins.
Philippe Costet

Pharmacol Ther· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.
Bertrand Cariou, Khadija Ouguerram, Yassine Zaïr, Raphael Guerois, Cédric Langhi, Philippe Costet

Arterioscler Thromb Vasc Biol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
Cédric Langhi, Cédric Le May, Valéry Gmyr, Brigitte Vandewalle, Julie Kerr-Conte, Philippe Costet

Biochem Biophys Res Commun· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes.
Sanae Kourimate, Maud Chétiveaux, Anne Laure Jarnoux, Florent Lalanne, Philippe Costet

Atherosclerosis· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia.
Cédric Le May, Sanae Kourimate, Cédric Langhi, Maud Chétiveaux, Anne Jarry, Philippe Costet

Arterioscler Thromb Vasc Biol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galactosylated multimodular lipoplexes for specific gene transfer into primary hepatocytes.
Emilie Letrou-Bonneval, Raphaël Chèvre, Olivier Lambert, Philippe Costet, Corinne André

J Gene Med· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
Philippe Costet, Michel Krempf, Bertrand Cariou

Trends Biochem Sci· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Sanae Kourimate, Cédric Le May, Cédric Langhi, Anne Laure Jarnoux, Khadija Ouguerram, Philippe Costet

J Biol Chem· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes.
Cédric Langhi, Cédric Le May, Sanae Kourimate, Sandrine Caron, Bart Staels, Philippe Costet

FEBS Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
Gilles Lambert, Anne-Laure Jarnoux, Thierry Pineau, Olivier Pape, Maud Chetiveaux, Philippe Costet

Endocrinology· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9: a promising therapeutic target for dyslipidemias?
Gilles Lambert, Michel Krempf, Philippe Costet

Trends Endocrinol Metab· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.
Philippe Costet, Bertrand Cariou, Gilles Lambert, Florent Lalanne, Bernard Lardeux

J Biol Chem· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis